MyoKardia, a company focused on developing innovative heart disease therapeutics, has appointed Mark Perry to its board of directors. Mr Perry currently serves as chair of the Pathway Therapeutics board and a director of Nvidia Corporation. Between 1994 and 2007 he worked at Gilead Sciences in roles including CFO and executive vice-president of operations.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August through September 2013.

Asia life science-focused VC firms*

A new joint Australia/New Zealand fund to support the commercialisation of intellectual property deriving from academic research has made its first investment, in an oncology therapeutics venture.